Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

2.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.

3.

Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis.

Roule V, Ardouin P, Repessé Y, Le Querrec A, Blanchart K, Lemaitre A, Sabatier R, Borel-Derlon A, Beygui F.

Clin Appl Thromb Hemost. 2018 Oct;24(7):1109-1116. doi: 10.1177/1076029618772354. Epub 2018 May 2.

PMID:
29719963
4.

Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeyssens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z.

Vox Sang. 2018 Feb;113(2):120-127. doi: 10.1111/vox.12624. Epub 2017 Dec 13.

PMID:
29238971
5.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
6.

A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.

Lambert T, Rothschild C, Volot F, Borel-Derlon A, Trossaërt M, Claeyssens-Donadel S, Attal S.

Transfusion. 2017 Apr;57(4):1066-1071. doi: 10.1111/trf.13988. Epub 2017 Mar 24.

PMID:
28337764
7.

F376A/M388A-solulin, a new promising antifibrinolytic for severe haemophilia A.

Parcq J, Petersen KU, Borel-Derlon A, Gautier P, Ebel M, Vivien D, Repessé Y.

Haemophilia. 2017 Mar;23(2):319-325. doi: 10.1111/hae.13126. Epub 2016 Dec 8.

PMID:
27928886
8.

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study.

Vautier M, de Boysson H, Creveuil C, Repesse Y, Borel-Derlon A, Troussard X, Damaj GL, Bienvenu B, Gautier P, Aouba A.

Medicine (Baltimore). 2016 Nov;95(48):e5232.

9.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.

10.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.

PMID:
26791163
11.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C.

Haemophilia. 2016 Jan;22 Suppl 1:1-24. doi: 10.1111/hae.12860.

12.

Ability of hemostatic assessment to detect bleeding disorders and to predict abnormal surgical blood loss in children: a systematic review and meta-analysis.

Guay J, Faraoni D, Bonhomme F, Borel Derlon A, Lasne D.

Paediatr Anaesth. 2015 Dec;25(12):1216-26. doi: 10.1111/pan.12723. Epub 2015 Oct 15.

PMID:
26467201
13.

Endovascular abdominal aortic aneurysm repair in a mild haemophilia A patient: a case report.

Gautier P, Repesse Y, Joguet E, Troussard X, Borel-Derlon A, Berger L.

Haemophilia. 2015 May;21(3):e232-5. doi: 10.1111/hae.12640. Epub 2015 Feb 16. No abstract available.

PMID:
25684019
14.

EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.

Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel-Derlon A, Bardoulat I, Maurel F, Woronoff-Lemsi MC; EQOFIX Study Group.

Transfusion. 2015 Jul;55(7):1787-97. doi: 10.1111/trf.13016. Epub 2015 Feb 5.

PMID:
25652955
15.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.

Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S.

Blood. 2014 Jan 2;123(1):121-5. doi: 10.1182/blood-2013-04-495853. Epub 2013 Sep 6.

16.

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Repessé Y, Peyron I, Dimitrov JD, Dasgupta S, Moshai EF, Costa C, Borel-Derlon A, Guillet B, D'Oiron R, Aouba A, Rothschild C, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium.

Haematologica. 2013 Oct;98(10):1650-5. doi: 10.3324/haematol.2013.084665. Epub 2013 May 28.

17.

Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.

Grosbois SS, Brionne MF, de Longcamp AL, Gautier P, V Kaveri S, Borel-Derlon A, Repessé Y.

Haemophilia. 2013 Mar;19(2):322-9. doi: 10.1111/hae.12067. Epub 2012 Dec 6.

PMID:
23216758
18.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
19.

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S.

Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3.

20.

Patient resources in the therapeutic education of haemophiliacs in France: their skills and roles as defined by consensus of a working group.

Wintz L, Sannié T, Ayçaguer S, Guerois C, Bernhard JP, Valluet D, Borel-Derlon A, Guillon P, Fondanesche C, Lambert T, Meunier S, Alliaume N, Gagnayre R.

Haemophilia. 2010 May;16(3):447-54. doi: 10.1111/j.1365-2516.2009.02163.x. Epub 2010 Jan 18.

PMID:
20088955
21.

[French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].

Meunier S, Trossaërt M, Berger C, Borel-Derlon A, Dirat G, Donadel-Claeyssens S, Assolant AD, Guérois C, Lutz P, Rafowicz A, Rothschild C, Chambost H; Groupe Prophylaxie CoMETH.

Arch Pediatr. 2009 Dec;16(12):1571-8. French.

PMID:
19960603
22.

Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.

Wootla B, Mahendra A, Dimitrov JD, Friboulet A, Borel-Derlon A, Rao DN, Uda T, Borg JY, Bayry J, Kaveri SV, Lacroix-Desmazes S.

FEBS Lett. 2009 Aug 6;583(15):2565-72. doi: 10.1016/j.febslet.2009.07.009. Epub 2009 Jul 15.

23.

[Acquired von Willebrand syndrome: from diagnosis to treatment].

Bustany S, Gautier P, Lequerrec A, Troussard X, Ollivier Y, Borel-Derlon A.

Pathol Biol (Paris). 2009 Nov-Dec;57(7-8):536-42. doi: 10.1016/j.patbio.2008.11.005. Epub 2009 Feb 3. French.

PMID:
19193498
24.

Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.

Stieltjes N, Torchet MF, Misrahi L, Roussel-Robert V, Lambert T, Guérois C, Bertrand MA, Briquel ME, Borel-Derlon A, Dirat G.

Blood Coagul Fibrinolysis. 2009 Jan;20(1):4-11.

PMID:
20527720
25.

A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.

Robert-Ebadi H, Le Querrec A, de Moerloose P, Gandon-Laloum S, Borel Derlon A, Neerman-Arbez M.

Blood Coagul Fibrinolysis. 2008 Oct;19(7):697-9. doi: 10.1097/MBC.0b013e3282f544ee.

PMID:
18832913
26.

Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.

Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S.

J Immunol. 2008 Jun 1;180(11):7714-20.

27.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V.

Haemophilia. 2007 Sep;13(5):502-7.

PMID:
17880436
28.

Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.

Repessé Y, Slaoui M, Ferrandiz D, Gautier P, Costa C, Costa JM, Lavergne JM, Borel-Derlon A.

J Thromb Haemost. 2007 Jul;5(7):1469-76. Epub 2007 Apr 18.

29.

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.

Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.

J Thromb Haemost. 2007 Jun;5(6):1115-24.

30.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S.

Blood. 2007 Jan 15;109(2):610-2. Epub 2006 Sep 19.

31.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T; MHAI Study Group.

Semin Hematol. 2006 Jan;43(1 Suppl 1):S3-9.

PMID:
16427382
32.

Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.

Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, Federici AB, Mannucci PM.

J Thromb Haemost. 2005 Oct;3(10):2219-27.

33.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups.

Blood. 2006 Jan 1;107(1):46-51. Epub 2005 Sep 15.

34.

Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases.

Slaoui M, Lambert T, Stieltjes N, Claeyssens S, Borel-Derlon A; Study Group.

Blood Coagul Fibrinolysis. 2004 Oct;15(8):687-91.

PMID:
15613924
35.

Experience with use of recombinant activated factor VII.

Divanon F, Hecquard C, Borel-Derlon A.

J Clin Pharm Ther. 2002 Apr;27(2):133-8.

PMID:
11975698
36.

Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.

Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY.

BJOG. 2001 Nov;108(11):1134-40.

37.

Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease.

Nurden P, Chretien F, Poujol C, Winckler J, Borel-Derlon A, Nurden A.

Br J Haematol. 2000 Sep;110(3):704-14.

PMID:
10997984
38.

Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.

Viallard JF, Pellegrin JL, Vergnes C, Borel-Derlon A, Clofent-Sanchez G, Nurden AT, Leng B, Nurden P.

Br J Haematol. 1999 May;105(2):532-7.

PMID:
10233433
39.

French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.

Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, Goudemand J, Parquet A, Peynet J, Vicariot M, Beurrier P, Claeyssens S, Durin A, Faradji A, Fressinaud E, Gaillard S, Guérin V, Guérois C, Pernod G, Pouzol P, Schved JF, Gazengel C.

Thromb Haemost. 1998 Nov;80(5):779-83.

PMID:
9843171
40.

[Which perioperative therapeutic strategies in constitutional hemostasis disorders?].

Borel-Derlon A.

Ann Fr Anesth Reanim. 1998;17 Suppl 1:10s-13s. Review. French.

PMID:
9750672
41.

[Digestive hemorrhage disclosing an angiodysplasia and von Willebrand disease type 2].

Lefrançois C, Dubus L, Maurel J, Chiche L, Lavergne JM, Borel-Derlon A.

Ann Fr Anesth Reanim. 1997;16(8):978-81. French.

PMID:
9750649

Supplemental Content

Loading ...
Support Center